Immuneel is bringing breakthrough cancer treatment to India. Affordably.
Cell, gene and immunotherapy are at the frontier of cancer treatment, offering real hope to millions. In the few countries, where cell therapies are available, these are very expensive, and access is limited.
Immuneel, led by a group of healthcare visionaries across US & India, is making cell therapies affordable and accessible in India, for India.
Using immune cells to fight cancer
Immuneel is pioneering cell and gene therapies such as Chimeric Antigen Receptor T cell therapy (CAR-T cell therapy) in India. CAR-T cell therapies use genetically modified human immune cells to fight cancer.
Therapies based on this radical idea are being developed globally and Immuneel is working to make this real in India.
Ending the wait for millions
Immuneel offers hope for cancer patients in India. In spite of a rich talent pool of scientists, researchers, specialist physicians and modern hospitals, India lags in access to new and advanced therapies. Immuneel, through its offerings, aims to address the unmet needs of India’s burgeoning cancer populace.
Immuneel is well positioned to offer advanced options for care, improve access and drive better patient outcomes.
Calling for partners, today
Partners are intrinsic to Immuneel’s plans to make a difference. We are collaborating with the world’s best to develop and deliver high quality cell therapies affordably. Our talented team, partners and investors are powering our crusade.
Join us.
What’s happening?
Recognitions for Immuneel
Wins ‘Most Promising Cell & Gene Therapy Startup in APAC’ at the Asia Pacific Cell & Gene Therapy Excellence Awards 2023, IMAPAC, ‘Innovation in Cell and Gene Therapy’s’ at the Endpoints 11 Awards event, ‘Innovation in Cell and Gene Therapy’ at BioPharma Honours 2023 & ‘CGCS Pioneers Award’ at International Cell & Gene Therapy China Summit & Exhibition 2024.
